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background:  Observational data indicate that increased myeloperoxidase (MPO) levels may be associated with increased risk of 
development of acute coronary syndrome (ACS) in patients with stable coronary artery disease (CAD). We performed a meta-analysis of 
observational studies to study the relationship between increased MPO and ACS among patients presenting with stable CAD and those 
presenting with ACS.
methods:  PubMed was searched from 1990 to September 2014 to identify the studies pertaining to the MPO levels and ACS among 
patients with and without stable CAD. Using the inverse variance method, we created a random effects model to determine the effect size 
via standardized mean difference (SMD) for continuous outcomes and relative risk (RR) for discrete outcomes.
Results:  A total of 9 studies (5 in CAD, 772 patients and 4 in ACS, 1166 patients) were included in the final analysis. There was a 
significant relationship between MPO levels and future risk for development of ACS in patients with stable CAD (SMD= 2.13, 95% CI=1.11-
3.14, I2=96.7%). However, when compared with patients presenting without ACS, no relationship was found between ACS and MPO levels 
(RR= 1.98, 95%CI=0.78-4.9, I2=81).
conclusion:  MPO levels are associated with increased risk of future development of ACS in patients with stable CAD. However, among 
patients who present with ACS, the levels are not significantly increased compared with controls. We recommend that MPO levels should 
be considered in the risk prediction models of ACS.
